AKT1 and systemic sclerosis: Therefore, simultaneous targeting of both mTORC1 and mTORC2 to effectively block the PI3K/Akt/mTOR pathway seems imperative, and it is vital, as such a strategy has led to the discovery and development of new second-generation inhibitor molecules against SSc.